IGA NEPHROPATHY (IGAN)
Clinical trials for IGA NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to control kidney disease in patients not helped by standard care
Disease control Not yet recruitingThis study tests an experimental drug called SLN12140 in 48 adults with IgA nephropathy, a kidney disease that is not well controlled with current treatments. Participants will receive either the drug or a placebo by injection for 36 weeks, and those who may benefit can continue …
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 06:10 UTC
-
Swiss study to track kidney Drug's Real-World impact
Disease control Not yet recruitingThis study will follow 50 adults with IgA nephropathy who are taking sparsentan. Researchers want to see how the drug affects protein in the urine (albuminuria), a key marker of kidney health. The study is observational, meaning no new treatment is given—just careful tracking of …
Matched conditions: IGA NEPHROPATHY (IGAN)
Sponsor: Waid City Hospital, Zurich • Aim: Disease control
Last updated May 26, 2026 06:04 UTC
-
Experimental cell injection targets Hard-to-Treat kidney diseases
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called GT719 in about 30 adults with immune-mediated kidney diseases such as IgA nephropathy and membranous nephropathy. The study aims to check the safety of the treatment and find the best dose. Participants receive a single injec…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated May 26, 2026 05:59 UTC
-
Engineered immune cells take aim at Hard-to-Treat kidney disease
Disease control Not yet recruitingThis early-stage study tests a new treatment for people with severe autoimmune kidney diseases (lupus nephritis, IgA nephropathy, or membranous nephropathy) that have not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-γδ T cells) design…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: Air Force Military Medical University, China • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Herbal granules aim to reduce kidney damage in IgA patients
Disease control Not yet recruitingThis study tests whether Shenqi Yishen Granules, a traditional Chinese medicine, can reduce protein in the urine of adults with IgA nephropathy, a kidney disease. About 102 participants will receive either the granules or a placebo to compare effects and safety. The goal is to se…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: NA • Sponsor: Keda Lu • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New kidney drug tested in people with mild to moderate impairment
Knowledge-focused Not yet recruitingThis early-stage study tests a single injection of RG002C0106 in 24 adults to see how kidney function affects the drug's safety and processing in the body. Half of the participants have normal kidneys, and half have mild-to-moderate kidney impairment. The goal is to gather safety…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE1 • Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. • Aim: Knowledge-focused
Last updated May 26, 2026 06:00 UTC